Reduction in Developmental Coordination Disorder with Neonatal Caffeine Therapy - 22/07/14

Doi : 10.1016/j.jpeds.2014.04.016

Lex W. Doyle, MD ^1,², Barbara Schmidt, MD, MSc ^3,⁹, Peter J. Anderson, PhD ², Peter G. Davis, MD ^1,², Diane Moddemann, MD ⁴, Ruth E. Grunau, PhD ⁵, Karel O'Brien, MB BCh BAO ⁶, Koravangattu Sankaran, MD ⁷, Eric Herlenius, MD, PhD ⁸, Robin Roberts, MSc ⁹
on behalf of the
Caffeine for Apnea of Prematurity Trial investigators^{^∗}
List of all investigators of the CAP Trial are available at www.jpeds.com/ (Appendix).
¹ Department of Obstetrics and Gynecology, University of Melbourne and The Royal Women's Hospital, Melbourne, Victoria, Australia
² Murdoch Childrens Research Institute, Melbourne, Victoria, Australia
³ Division of Neonatology, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA
⁴ University of Manitoba, Winnipeg, Canada
⁵ University of British Columbia, Vancouver, Canada
⁶ Mount Sinai Hospital, Toronto, Ontario, Canada
⁷ University of Saskatchewan, Saskatoon, Canada
⁸ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
⁹ Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

Abstract

Objective

To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD).

Study design

Children in the Caffeine for Apnea of Prematurity trial were assessed for motor performance (Movement Assessment Battery for Children [MABC]), clinical signs of cerebral palsy, and Full-Scale IQ at 5 years of age by staff who were unaware of the children's treatment group. DCD was defined as MABC <5th percentile in children with a Full-Scale IQ >69 who did not have a diagnosis of cerebral palsy.

Results

There were 1433 children with known MABC corrected-age percentile as well as known Full-Scale IQ at 5 years and cerebral palsy status, of whom 735 had been randomly assigned to caffeine and 698 to placebo therapy. The rate of DCD was lower in those treated with caffeine (11.3%) than in the placebo group (15.2%) (OR adjusted for center and baseline covariates, 0.71, 95% CI, 0.52-0.97; P = .032).

Conclusions

Neonatal caffeine therapy for apnea of prematurity reduces the rate of DCD at 5 years of age. As more children have DCD than have cerebral palsy, this is an important additional benefit from neonatal caffeine treatment.

Le texte complet de cet article est disponible en PDF.

Keyword : CAP, DCD, MABC, MRI

Plan

Methods

Results

Discussion

	Supported by the Canadian Institutes of Health Research (MCT 13288), the National Health and Medical Research Council of Australia (108706 and CCRE 546519), and Victorian Government's Operational Infrastructure Support Program. The authors declare no conflicts of interest.
	Registered with ClinicalTrials.gov: NCT00182312.

Export

Vol 165 - N° 2

P. 356 - août 2014 Retour au numéro

Article précédent

Knowledge, Attitudes, and Practices Related to Pet Contact by Immunocompromised Children with Cancer and Immunocompetent Children with Diabetes
Jason W. Stull, Jason Brophy, Jan M. Sargeant, Andrew S. Peregrine, Margaret L. Lawson, Raveena Ramphal, Lindy Samson, Jennifer Bowes, J. Scott Weese

| Article suivant

Impaired Range of Motion of Limbs and Spine in Chronic Fatigue Syndrome
Peter C. Rowe, Colleen L. Marden, Marissa A.K. Flaherty, Samantha E. Jasion, Erica M. Cranston, Allison S. Johns, John Fan, Kevin R. Fontaine, Richard L. Violand

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Reduction in Developmental Coordination Disorder with Neonatal Caffeine Therapy - 22/07/14

Abstract

Objective

Study design

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL